Laboratory Identification of Lupus Anticoagulants

被引:42
作者
Kershaw, Geoffrey [1 ]
Suresh, Sasikala [2 ]
Orellana, Daniel [1 ]
Nguy, Yun-Mi [1 ]
机构
[1] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2065, Australia
[2] Dist Gen Hosp, Dept Haematol, Negambo, Sri Lanka
关键词
lupus anticoagulant; diluted Russell viper venom time; activated partial thromboplastin time; mixing test; ANTIPHOSPHOLIPID SYNDROME; COAGULATION ASSAYS; TERTIARY PRACTICE; CLINICAL AUDIT; NORMAL PLASMA; DIAGNOSIS; GUIDELINES; CRITERIA; SUBCOMMITTEE; RIVAROXABAN;
D O I
10.1055/s-0032-1311991
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The main laboratory characteristic of lupus anticoagulants (LA) is their ability to prolong phospholipid-dependent clotting time in vitro. The laboratory demonstration of LA requires a systematic approach combined with an awareness of the many variables that can affect test results. The ideal testing procedures are those sensitive enough to detect weak LA and specific enough so as not to produce incorrect conclusions. International guidelines have been published to assist laboratories in applying correct testing processes. The most recently published guidelines from the International Society on Thrombosis and Haemostasis update the criteria for detecting the presence of LA that were presented in the 1995 guidelines. Some of the specific recommendations relate to the key areas of setting cut-off levels for screening, mixing, and confirmatory procedures. The more challenging aspects of testing for LA include maintaining sensitivity and specificity of the assays, especially in the presence of anticoagulant therapy.
引用
收藏
页码:375 / 384
页数:10
相关论文
共 31 条
[11]   Clinical audit of antiphospholipid antibody testing in tertiary practice: towards improved relevance in thrombophilia investigations [J].
Favaloro, E. J. ;
Reben, R. ;
Mohammed, S. ;
Koutts, J. .
INTERNAL MEDICINE JOURNAL, 2012, 42 (04) :427-434
[12]   Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required [J].
Favaloro, E. J. ;
Bonar, R. ;
Zebeljan, D. ;
Kershaw, G. ;
Marsden, K. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (12) :2828-2831
[13]   Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part II-Lupus Anticoagulant [J].
Favaloro, Emmanuel J. ;
Bonar, Roslyn ;
Marsden, Katherine .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (04) :404-411
[14]   Laboratory testing of anticoagulants: the present and the future [J].
Favaloro, Emmanuel J. ;
Lippi, Giuseppe ;
Koutts, Jerry .
PATHOLOGY, 2011, 43 (07) :682-692
[15]   A clinical audit of congenital thrombophilia investigation in tertiary practice [J].
Favaloro, Emmanuel J. ;
Mohammed, Soma ;
Pati, Nalini ;
Ho, Man Yuk ;
Mcdonald, David .
PATHOLOGY, 2011, 43 (03) :266-272
[16]  
Gosselin RC, 2004, ARCH PATHOL LAB MED, V128, P1142
[17]   Guidelines on the investigation and management of the antiphospholipid syndrome [J].
Greaves, M ;
Cohen, H ;
Machin, SJ ;
Mackie, I .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) :704-715
[18]   Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays [J].
Hillarp, A. ;
Baghaei, F. ;
Blixter, I. Fagerberg ;
Gustafsson, K. M. ;
Stigendal, L. ;
Sten-Linder, M. ;
Strandberg, K. ;
Lindahl, T. L. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) :133-139
[19]  
Jacobsen EM, 2000, THROMB HAEMOSTASIS, V83, P704
[20]   Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene [J].
Jacobsen E.M. ;
Trettenes E.J. ;
Wisløff F. ;
Abildgaard U. .
Thrombosis Journal, 4 (1)